



**BIostatISTICS
BIOINFORMATICS**
Supporting Biomedical Research



**JOHNS HOPKINS
MEDICINE**

HDL Sub-fractions and CVD Morbidity/Mortality in African Americans

*Associations of HDL Subclasses and Incident Cardiovascular
Events in African Americans from the Jackson Heart Study*


Michael E Griswold, PhD

Dir for Data Analytics, Jackson Heart Study

Professor & Director, Center of Biostatistics & Bioinformatics, UMMC


presenting on behalf of Parag Joshi, MD, Seth Lirette, MS, Seth Martin, MD, Michael Blaha, MD, MPH, Krishnaji Kulkarni, PhD, Adolfo Correa, MD, PhD, Herman Taylor, MD, and Steven Jones, MD for the Lipoprotein Investigators Collaborative (LIC)

Background: Cholesterol and CVD



- Guidelines have moved from measuring just TC to TC+TG to LDLc+HDLc+TG

If you wish to make an apple pie truly from scratch, you must first invent the universe. ~Carl Sagan



Castelli WP, Garrison RJ, Wilson PWF, et al.
JAMA 1986;256:2835-2838.

Note: Please don't ever make a 3D BarChart

Background:



VLDL subcomponents

LDL subcomponents

HDL subcomponents

Hydrated Densities:


- VLDL: $\sim < 1.006$ g/ml
- LDL: ~ 1.006 - 1.063 g/ml
- HDL: ~ 1.063 - 1.21 g/ml
 - HDL2: 1.063 - 1.125 g/ml
 - HDL3: 1.125 - 1.21 g/ml



- Size + Composition:
 - Apo (A-I, A-II, B), ...
- A more sophisticated understanding of lipoproteins has been pursued...

3

Background: apoA-I -> HDL3 -> HDL2 -> ...



Background: Mixed Results

“Large Buoyant” (HDL₂-c) versus “Small Dense” (HDL₃-c)


- **Nice Review:**
Superko (2012), *High Density Lipoprotein subclasses and their relationship to Cardiovascular Disease*, J Clin Lipid (6) 496-523
- **37 Case-Control Studies**
 - N=53 comparisons
 - 41 (78%) Men only
 - 26% HDL2c, 11% HDL3c
 - 17% neither, 45% both
- **8 Prospective Studies**
 - 1 HDL2c, 3 HDL3c, 4 both
- **Trials: AIMHIGH & ILLUMINATE (↑HDL2)**
 - Terminated early (eff/safety)

Study	Design	Methodology	HDL-C	HDL2	HDL3
Alagani et al., 2002 ³⁸	Carotid B-mode ultrasonography of IMT in 89 asymptomatic	Ultracentrifugation	HDL-C inversely correlated with IMT when adjusted	HDL2-C inversely correlated with IMT when adjusted	HDL3-C not correlated
Table 1 (continued)					
Alger et al., 1995 ³⁹	Study	Design	Methodology	HDL-C	HDL2
	Jayakumar et al., 1993 ⁴⁰	55 men with coronary artery disease	Polyethylene glycol-6000 precipitation	HDL-C unrelated to CAD	HDL2-C unrelated to
	Jiang et al., 1995 ⁴¹	78 Chinese cases undergoing coronary angiography			HDL2-C inversely correlated with CAD (r = -0.3)
Table 2. Cross-sectional case vs control comparisons between diseased and healthy subjects					
Breier et al., 1995 ⁴²	Study	Design	Methodology	HDL-total	HDL2
	Alexandri et al., 1985 ⁴³	40 patients (24 men, 16 women) with	Dextran sulfate precipitation	HDL-C lower but not significantly so	HDL2-C low
Table 2 (continued)					
Lamon et al., 1994 ⁴⁴	Study	Design	Methodology	HDL-total	HDL2
	A. Hui et al., 1997 ⁴⁵	30 male myocardial infarction survivors vs 30 controls, 40-60	Two-step serial centrifugation		
Table 2 (continued)					
Drexl et al., 1992 ⁴⁶	Study	Design	Methodology	HDL-total	HDL2
	Levy et al., 1994 ⁴⁷	Angiographically documented CAD in 339 patients (89% male) vs 105	HDL stepwise precipitation by dextran sulfate	HDL-C lower: 1.18 ± 0.02 vs 1.41 ± 0.04 mmol/L	
Freedman et al., 1995 ⁴⁸	Study	Design	Methodology	HDL-total	HDL2
	Manda et al., 2011 ⁴⁹	116 male myocardial infarction survivors <45 years and in 116 age-matched controls	Preparative ultracentrifugal spin at d = 1.125 g/mL for HDL3 and HDL2 calculated as difference	HDL-C lower: 1.12 ± 1.45 ± 0.04 mmol/L	
Giral et al., 1994 ⁵⁰	Study	Design	Methodology	HDL-total	HDL2
	Miller et al., 1995 ⁵¹	55 men (25 <45 and 30 >45 years old)	Polyethylene glycol-6000	HDL-C lower, i.e., <4.0 ± 0.68 ± 0.03 vs 1.1 ± 0.11	
	Felkin et al., 1985 ⁵²	63 male claudication patients vs 63 controls	% distribution from polyacrylamide gradient gel electrophoresis	HDL-C lower: 1.61	
Table 2 (continued)					
Alger et al., 1995 ³⁹	Study	Design	Methodology	HDL-C	HDL2
	Franceschi et al., 1991 ⁵³	100 men with coronary artery disease (50 diabetic, 50 nondiabetic) vs 81 men without CAD (50 diabetic, 31 nondiabetic)	Ultracentrifugation for HDL3 and HDL2, HDL subclasses by 4/3% polyacrylamide gel		
Brook et al., 1982 ⁵⁴	Study	Design	Methodology	HDL-C	HDL2
	Kahle et al., 1994 ⁵⁵	100 men with coronary artery disease (50 diabetic, 50 nondiabetic) vs 81 men without CAD (50 diabetic, 31 nondiabetic)	Ultracentrifugation for HDL3 and HDL2, HDL subclasses by 4/3% polyacrylamide gel		

Background:

AIM


To examine **HDLc & HDLc-subclass (HDL2c, HDL3c)** relationships with **incident cardiovascular events (CHD, Fatal CHD, MI, Int. Cardiac Procs)** in **African Americans** from the **Jackson Heart Study**, while accounting for differential content markers (apo's).



HDLc?

HDL2?

HDL3?



Methods:

The Jackson Heart Study

- **Study:** Prospective, population-based, observational study of **5,301 African Americans** aged 20-84 from Jackson, MS; up to 8 years of F/U from 2000 to 2008 (median: ~5 yrs)
- **Outcomes:** Coronary Heart Disease (**CHD**) events including Fatal CHD, Myocardial Infarction (MI), Revascularizations
- **Lipoprotein measures:** Cholesterol subfractions by **density gradient ultracentrifugation (VAP test, Atherotech, Birmingham, AL)**; Apolipoprotein A1 and B (**Abbott** Diagnostics, Lake Forest, IL). N= 4,722 markers measured from Exam 1 (baseline).
- **Analyses:** Cox PHM and logistic regression examining HDL subclasses and CHD; adjusted for combinations of:
 - age, sex, BMI, education, alcohol, smoking, SBP, DBP, lipid-altering medications, and apolipoproteins (ApoA-1, ApoB)



7

Results:


*144 CHD events: 27 CHD deaths;
78 MIs; 39 revascularizations

Baseline Characteristics

Variable		No CHD (n=4,578)	CHD* (n=144)	p-value
Gender, Female		64%	60%	0.29
Diabetes		17%	43%	<0.001
Education	< High School	17%	29%	<0.001
	High School/GED	42%	44%	
	College	41%	27%	
Smoking Status	Never	69%	56%	<0.001
	Former	18%	31%	
	Current	13%	14%	
Alcohol Use		47%	37%	0.015
Age (years)		53.9 (12.8)	64.3 (9.8)	<0.001
Body Mass Index (kg/m ²)		31.8 (7.3)	30.3 (6.1)	0.015
Waist Circumference (cm)		100.6 (16.3)	101.8 (13.7)	0.37
Systolic Blood Pressure (mmHg)		126.5 (18.2)	134.4 (19.9)	<0.001
Diastolic Blood Pressure (mmHg)		79.1 (10.4)	76.9 (11.2)	0.015
Lipid-altering Medications		11%	23%	<0.001

Participants with CHD were sicker in general (careful with confounding)

8



Results:


CHD Multivariable Survival Analyses across adjustment models

Model	HDL-C	HDL2-C	HDL3-C
Basic Adj: Age, Sex, BMI, Educ, Alcohol, Smoking, Blood Pressure, and lipid-meds	0.79 (0.65,0.96) p=0.020	0.88 (0.73,1.06) p=0.186	0.76 (0.62,0.92) p=0.005
Basic + ApoA-1	0.73 (0.50,1.06) p=0.099	1.00 (0.75,1.32) p=0.981	0.60 (0.41,0.88) p=0.009
Basic + ApoB	0.82 (0.67,1.00) p=0.055	0.92 (0.76,1.12) p=0.423	0.78 (0.64,0.95) p=0.013
Basic + ApoA-1 + ApoB	0.86 (0.57,1.31) p=0.489	1.19 (0.88,1.61) p=0.252	0.64 (0.43,0.96) p=0.030

10

Results:**Fully Adj. Models*


HDL subclasses and 8-Year CHD events



11

Results: *Shift in CHD joint distb (up & left) gives HDL3c some props*

Joint Distbs.

HDLc Reclass: Women

Risk Reclassification

Risk Reclassification


CHD Ptcpts		HDL3c		
		Low Risk	High Risk	Total
HDLc	Low Risk	91	24	115
		79.13	20.87	100
		63.19	16.67	79.86
	High Risk	0	29	29
		0	100	100
		0	20.14	20.14
N		91	53	144
Row %	Total	63.19	36.81	100
Cell %		63.19	36.81	100

Non-CHD Ptcpts		HDL3c		Total
		Low Risk	High Risk	
HDLc	Low Risk	3471	442	3913
		88.7	11.3	100
		75.82	9.65	85.47
	High Risk	2	663	665
		0.3	99.7	100
		0.04	14.48	14.53
Total		3473	1105	4578
		75.86	24.14	100
		75.86	24.14	100

***Note:** Be careful with Risk Reclassification statistics & interpretations. (NRI, IDI, etc.)*

Note: Be careful with Risk Reclassification statistics & interpretations. (NRI, IDI, etc.)


Discussion: Strengths/Limitations



- **Strengths:**
 - **Largest study** of HDLc subclasses in African Americans and cardiovascular risk to our knowledge
 - **Robust adjustment** including apolipoproteins (as opposed to total and LDL cholesterol and TGs)
- **Limitations:**
 - Cross-sectional measurements do not reflect accumulated or time-varying exposures
 - HDLc (and subclasses) may be poor surrogates for true HDL
 - Singular geographic location and ethnic group
 - Younger Participant Base (lower event numbers)
 - HDL functionality within these subclasses is to be determined, though this is an important step in better understanding of the HDL structure-function relationship

Discussion:


Interpretations & Implications



- Interpretations:
 - **HDL3c** appeared to drive relationships between overall HDLc and CHD endpoints in this sample of African Americans
- Implications:
 - Lipid and Lipoprotein **Subclasses** may offer increased risk stratification and early warning opportunities in similar African American populations, but too early now
- Future work:
 - Longitudinal Data and Risk Reclassification Modeling
 - LIC Consortium

15

Acknowledgements



- The Jackson Heart Study is supported by contracts N01-HC-95170, N01-HC-95171, N01-HC-95172 from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities, with additional support from the National Institute on Biomedical Imaging and Bioengineering.
- Lipoprotein Investigators Consortium:
 - Atherotech: Kris Kulkarni
 - Johns Hopkins SOM: Steven R. Jones, Michael J. Blaha, Seth S. Martin, Parag H. Joshi
 - Jackson Heart Study: Mike Griswold, Seth Lirette, Adolfo Correa, Herman Taylor
 - Oxford University: Arif Khokhar
 - University of Illinois: Peter Toth
 - Boston University: Ralph D'Agostino, Joseph Massaro
 - St. Luke's Mid-America Heart Institute: Philip Jones, Yan Li, John Spertus
 - Intermountain Medical Center: Heidi May, Brent Muhlestein, Jeffrey L. Anderson
- Our heartfelt thanks to all of the patients, providers, and staff who have worked to create and maintain this robust database

16

In Review:

Things often can look similar but can have important differences...



Gavin & Connor Griswold

Thanks!
Questions?

